Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the uses, mechanisms, and side effects of valproate in treating bipolar disorder, noting its first-line status for several manic conditions but also highlighting serious risks such as fetal abnormalities.

In this study, combining topical calcipotriol with mometasone results in greater improvement in alopecia areata treatment compared to using mometasone alone, as evidenced by a more significant reduction in SALT score over 24 weeks.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This study suggests that using nutrient antioxidants can significantly reduce the dose of prednisolone needed in alopecia areata patients while potentially enhancing hair growth and mitigating side effects.

This article rebuts a previous rejection of corticosteroid therapy for alopecia areata, reporting successful treatment in multiple patients with systemic and intralesional steroids and minimal side effects.

This study suggests that low alternating daily doses of sodium divalproate may be effective for migraine prevention, similarly to higher doses, but can still lead to modest weight gain.

This study found that inhaled fluticasone for 11 months did not adversely affect the immune function or response to vaccination in horses with heaves.

In this study, the side effects of long-term sodium valproate treatment for refractory epilepsy were generally slight and transient, with severe side effects not observed.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

This review, drawing on literature and personal experience, suggests that sodium valproate is a safe and effective antiepileptic drug for various epileptic conditions in children and adults, including the elderly.

This review discusses the effects of valproic acid on immune cell activation and gene expression, potentially influencing infection outcomes and suggesting its promise for autoimmune and hypersensitivity condition management.

This study reports that alopecia may develop in patients with chronic exposure to high plasma concentrations of valproate, but resolved after dose reduction or treatment discontinuation.

This review discusses the development of valproate as an effective monotherapy for controlling generalized seizures and reports no new clinical results.

In this study, beagle dogs treated with hydrocortisone 17-butyrate 21-propionate ointment showed various toxic effects, including acne-like skin changes and organ atrophy, which returned to normal after a recovery period.

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

In this study, researchers found that metformin improved glycaemic control and other metabolic parameters in non-diabetic patients on glucocorticoid treatment, also reducing pneumonia risk and hospital admissions, suggesting a potential advantage for routine use in this population.

This study suggests that repeated trilostane treatment increases brain allopregnanolone levels and delays epileptogenesis in rats after status epilepticus.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This study found that sodium valproate effectively controlled petit mal seizures in children resistant to other anticonvulsants but was less effective for other seizure types.

This study found that thrombocytopenia is a common side effect of valproic acid, affecting up to 54% of elderly patients, but it is under-investigated despite significant therapeutic consequences.

This case study reports on a 23-month-old child who developed onychomadesis after valproic acid treatment, which resolved on its own without further intervention.

This study concluded that topical betamethasone valerate lotion is more effective than 15% lactic acid solution for managing multiple patchy alopecia areata over a 12-week period in a sample of 50 patients.

This study found no statistically significant difference in the severity of insect bite hypersensitivity symptoms between horses receiving a nicotinamide supplement and those receiving a placebo.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.

This study found that patients with alopecia areata and less than 50% hair loss showed a good response to pulse therapy with methylprednisolone, while those with more extensive hair loss also improved but required more courses.

This study presents a case of a 24-year-old man who developed mild transaminitis and rhabdomyolysis within 24 hours of starting valproic acid for seizures, with symptom resolution following drug cessation.

In this study, oral mini-pulse methylprednisolone therapy for alopecia areata was reported to be effective and safe over 6 months, with 82.2% of patients recovering well and no adverse events observed.

In this case study, medical management with trilostane improved clinical signs and normalized serum chemistry in a dog diagnosed with adrenal-dependent hyperadrenocorticism over 80 weeks of treatment.

Methylprednisolone treatment helps most alopecia areata patients, but young age, extensive hair loss, and low vitamin D can affect results.

This article reviews alopecia treatment and reports a case where hair regrew rapidly with prednisolone, but fell out again after stopping the medication; no new results are presented.